Metastasis: A question of life or death

Nature Reviews Cancer

Volumn 6, Issue 6, 2006, Pages 449-458

  Mehlen, Patrick ^a   Puisieux, Alain ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL INVASION; CELL SURVIVAL; CIRCULATION; COLON CANCER; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; MATHEMATICAL MODEL; METASTASIS; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; APOPTOSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 33745684527     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1886     Document Type: Review

References (102)

1. Weigelt, B., Peterse, J. L. & van't Veer, L. J. Breast cancer metastasis: markers and models. Nature Rev. Cancer 5, 591-602 (2005).
2. Salvesen, G. S. & Dixit, V. M. Caspases: intracellular signaling by proteolysis. Cell 91, 443-446 (1997).
3. Zimmermann, K. C. & Green, D. R. How cells die: apoptosis pathways. J. Allergy Clin. Immunol. 108, S99-S103 (2001).
4. Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nature Rev. Mol. Cell Biol. 3, 401-410 (2002).
5. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). A seminal review describing the main rules that govern the transformation of normal human cells into malignant cancers.
6. Yin, C., Knudson, C. M., Korsmeyer, S. J. & Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640 (1997).
7. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
8. Fidler, I. J. & Nicolson, G. L. Fate of recirculating B16 melanoma metastatic variant cells in parabiotic syngeneic recipients. J. Natl Cancer Inst. 58, 1867-1872 (1977).
9. Liotta, L. A., Vembu, D., Saini, R. K. & Boone, C. In vivo monitoring of the death rate of artificial murine pulmonary micrometastases. Cancer Res. 38, 1231-1236 (1978).
10. Varani, J., Lovett, E. J., Elgebaly, S., Lundy, J. & Ward, P. A. In vitro and in vivo adherence of tumor cell variants correlated with tumor formation. Am. J. Pathol. 101, 345-352 (1980).
11. Inbal, B. et al. DAP kinase links the control of apoptosis to metastasis. Nature 390, 180-184 (1997). By using lung carcinoma clones, this study shows that the inhibition of the expression of DAPK, a positive mediator of apoptosis, favours the metastatic process.
12. Um, J. H. et al. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J. Pharmacol. Exp. Ther. 311, 1062-1070 (2004).
13. Glinsky, G. V., Glinsky, V. V., Ivanova, A. B. & Hueser, C. J. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 115, 185-193 (1997). Data showing that the metastatic potential of murine and human cancer cells is strictly associated with the increased resistance to apoptosis.
14. Del Bufalo, D., Biroccio, A., Leonetti, C. & Zupi, G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J. 11, 947-953 (1997). An elegant study showing that the overexpression of the anti-apoptotic oncoprotein BCL2 increases the metastatic potential of human breast cancer cells.
15. McConkey, D. J., Greene, G. & Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 56, 5594-5599 (1996).
16. Furuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C. & Isaacs, J. T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 2, 389-398 (1996).
17. Owen-Schaub, L. B., van Golen, K. L., Hill, L. L. & Price, J. E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 188, 1717-1723 (1998).
18. Thompson, T. C. et al. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene 10, 869-879 (1995).
19. Silvestrini, R. et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin. Cancer Res. 2, 2007-2013 (1996).
20. Lewis, B. C. et al. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell. Biol. 25, 1228-1237 (2005).
21. Ko, J. et al. Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice. Oncogene 23, 1950-1953 (2004).
22. Esteller, M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 4, 351-358 (2003).
23. Bao, S. et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5, 329-339 (2004).
24. Martin, S. S. & Vuori, K. Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochim. Biophys. Acta 1692, 145-157 (2004). A detailed analysis of the molecular mechanisms of apoptosis induced during anoikis and amorphosis.
25. Streuli, C. H. & Gilmore, A. P. Adhesion-mediated signaling in the regulation of mammary epithelial cell survival. J. Mammary Gland. Biol. Neoplasia 4, 183-191 (1999).
26. Martin, S. S. & Leder, P. Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2. Mol. Cell. Biol. 21, 6529-6536 (2001).
27. Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M. & Strasser, A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287-296 (1999).
28. Puthalakath, H. et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293, 1829-1832 (2001).
29. Zhu, Z. et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res. 61, 1707-1716 (2001).
30. FAK) in invasive human tumors. Cancer Res. 55, 2752-2755 (1995).
31. McLean, G. W. et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 18, 2998-3003 (2004).
32. Gentile, A. & Comoglio, P. M. Invasive growth: a genetic program. Int. J. Dev. Biol. 48, 451-456 (2004).
33. Camp, E. R. et al. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann. Surg. Oncol. 12, 273-281 (2005).
34. Peace, B. E., Toney-Earley, K., Collins, M. H. & Waltz, S. E. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res. 65, 1285-1293 (2005).
35. Zeng, Q. et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NKκB. J. Biol. Chem. 277, 25203-25208 (2002).
36. Pinkas, J., Martin, S. S. & Leder, P. Bcl-2-mediated cell survival promotes metastasis of EpH4 βMEKDD mammary epithelial cells. Mol. Cancer Res. 2, 551-556 (2004).
37. L as a suppressor of cytoskeleton-dependent death and that overexpression in mouse mammary epithelial cells does not induce primary tumour formation but strongly increases metastatic potential.
38. Olopade, O. I. et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3, 230-237 (1997).
39. Fernandez, Y., Gu, B., Martinez, A., Torregrosa, A. & Sierra, A. Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int. J. Cancer 101, 317-326 (2002).
40. Berezovskaya, O. et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 65, 2378-2386 (2005). Comprehensive work showing that the apoptosis-inhibitory protein XIAP contributes to the anoikis resistance of circulating metastatic prostate cancer cells.
41. Shen, T. L. et al. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J. Cell Biol. 169, 941-952 (2005).
42. Wyckoff, J. B., Jones, J. G., Condeelis, J. S. & Segall, J. E. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. 60, 2504-2511 (2000).
43. Fidler, I. J. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl Cancer Inst 45, 773-782 (1970).
44. Wong, C. W. et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 61, 333-338 (2001).
45. Luzzi, K. J. et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153, 865-873 (1998). References 43, 44 and 45 examine the fate of cancer cells in the blood stream and in the site of metastasis, aiming to identify mechanisms explaining the overall metastatic inefficiency.
46. Jakobisiak, M., Lasek, W. & Golab, J. Natural mechanisms protecting against cancer. Immunol. Lett. 90, 103-122 (2003).
47. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
48. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
49. Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492 (1985).
50. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (2001).
51. Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L. & Yokoyama, W. M. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl Acad. Sci. USA 97, 2731-2736 (2000).
52. Smyth, M. J. et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 200, 1325-1335 (2004).
53. Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cell Immunol. 214, 194-200 (2001).
54. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002).
55. Weiss, L., Elkin, G. & Barbera-Guillem, E. The differential resistance of B16 wild-type and F10 cells to mechanical trauma in vitro. Invasion Metastasis 13, 92-101 (1993).
56. Ziegler, T., Silacci, P., Harrison, V. J. & Hayoz, D. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 32, 351-355 (1998).
57. Wang, H. H. et al. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res. 60, 5862-5869 (2000).
58. Edmiston, K. H. et al. Role of nitric oxide and superoxide anion in elimination of low metastatic human colorectal carcinomas by unstimulated hepatic sinusoidal endothelial cells. Cancer Res. 58, 1524-1531 (1998).
59. Jaattela, M., Wissing, D., Kokholm, K., Kallunki, T. & Egeblad, M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J. 17, 6124-6134 (1998).
60. Kluger, H. M. et al. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res. 65, 5578-5587 (2005).
61. Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289-298 (2002).
62. Nikiforov, M. A. et al. p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 13, 1709-1719 (1996). Data showing that the inactivation of p53 in transformed mouse embryonic fibroblasts facilitates experimental metastasis by promoting the survival of tumour cells in circulation.
63. Schuler, M. & Green, D. R. Transcription, apoptosis and p53: catch-22. Trends Genet. 21, 182-187 (2005).
64. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nature Rev. Mol. Cell Biol. 4, 33-45 (2003).
65. Yu, Q., Toole, B. P. & Stamenkovic, I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 186, 1985-1996 (1997).
66. O'Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
67. O'Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996).
68. O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
69. Giehl, K. Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 386, 193-205 (2005).
70. Liao, Y. et al. Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. Hepatogastroenterology 47, 365-370 (2000).
71. Varghese, H. J. et al. Activated ras regulates the proliferation/ apoptosis balance and early survival of developing micrometastases. Cancer Res. 62, 887-891 (2002). By using in vivo video microscopy and detailed cell quantification, this study provides evidence for a direct role for Ras in the maintenance of metastatic growth by mediating a shift in the proliferation/ apoptosis balance.
72. Mehlen, P. The dependence receptor notion: another way to see death. Cell Death Differ. 12, 1003 (2005).
73. Mehlen, P. & Bredesen, D. E. The dependence receptor hypothesis. Apoptosis 9, 37-49 (2004).
74. Mehlen, P. & Thibert, C. Dependence receptors: between life and death. Cell Mol. Life Sci. 61, 1854-1866 (2004).
75. Bredesen, D. E., Mehlen, P. & Rabizadeh, S. Receptors that mediate cellular dependence. Cell Death Differ. 12, 1031-1043 (2005).
76. Wang, J. J. et al. Dimerization-dependent block of the proapoptotic effect of p75(NTR). J. Neurosci. Res. 60, 587-593 (2000).
77. Forcet, C. et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc. Natl Acad. Sci. USA 98, 3416-3421 (2001).
78. Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M. & Cheresh, D. A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. 155, 459-470 (2001).
79. Mehlen, P. & Furne, C. Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cell Mol. Life Sci. 62, 2599-2616 (2005).
80. Fearon, E. R. et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49-56 (1990).
81. Mehlen, P. & Fearon, E. R. Role of the dependence receptor DCC in colorectal cancer pathogenesis. J. Clin. Oncol. 22, 3420-3428 (2004).
82. Thiebault, K. et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc. Natl Acad. Sci. USA 100, 4173-4178 (2003).
83. Mehlen, P. et al. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 395, 801-804 (1998).
84. Llambi, F., Causeret, F., Bloch-Gallego, E. & Mehlen, P. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. EMBO J. 20, 2715-2722 (2001).
85. Mazelin, L. et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 431, 80-84 (2004). This paper suggests for the first time, using a mouse model, that dependence receptors might regulate tumorigenesis.
86. Llambi, F. et al. The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase. EMBO J. 24, 1192-1201 (2005).
87. Tanikawa, C., Matsuda, K., Fukuda, S., Nakamura, Y. & Arakawa, H. p53RDL1 regulates p53-dependent apoptosis. Nature Cell Biol. 5, 216-223 (2003).
88. Stupack, D. G. Integrins as a distinct subtype of dependence receptors. Cell Death Differ. 12, 1021-1030 (2005).
89. Stupack, D. G. et al. Potentiation of neuroblastoma metastasis by loss of caspase 8. Nature 439 95-99 (2006). This paper represents the first demonstration of a role for dependence receptors in metastasis regulation.
90. Hofmann, U. B., Houben, R., Brocker, E. B. & Becker, J. C. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87, 307-314 (2005).
91. Abraham, R. et al. Identification of MMP-15 as an anti-apoptotic factor in cancer cells. J. Biol. Chem. 280, 34123-34132 (2005).
92. Strand, S. et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23, 3732-3736 (2004).
93. Huber, M. A. et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 114, 569-581 (2004).
94. Chen, Z. F. & Behringer, R. R. Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev. 9, 686-699 (1995).
95. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004).
96. Maestro, R. et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13, 2207-2217 (1999).
97. Valsesia-Wittmann, S. et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6, 625-630 (2004). References 95, 96 and 97 show the oncogenic properties of H-Twist, highlighting its role as an anti-apoptotic factor (references 96 and 97), and establishing its implication in the metastatic process (reference 95).
98. Puisieux, A., Valsesia-Wittmann, S. & Ansieau, S. A twist for survival and cancer progression. Br. J. Cancer 94, 13-17 (2006).
99. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. & Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115 (1988).
100. Greenberg, N. M., et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92, 3439-3443 (1995)
101. Sierra, A. Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resist. Updat. 8, 247-257 (2005).
102. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nature Rev. Cancer 5, 876-885 (2005).